The Global Network for Neglected Tropical Diseases’ “End the Neglect” blog reports that the Dengue Vaccine Initiative has launched a redesigned website, including a new blog that “will include regular posts about the disease, dengue in the news, the work of DVI and the development of a dengue vaccine” (9/17).
UNICEF has released its 2012 partnership profiles, “short case studies which highlight specific partnership initiatives at global, regional and country levels” and “illustrate how partnerships have contributed to results, either the creation of innovation, policy advocacy, evidence generation, or provision of essential services,” according to UNICEF’s Partnerships webpage. Some of the organizations highlighted include the GAVI Alliance (.pdf), the Global Fund to Fight AIDS, Tuberculosis and Malaria (.pdf), and the Global Polio Eradication Initiative (.pdf) (9/17).
With nearly 6,000 reported cholera cases, including more than 100 deaths, Guinea is facing the worst cholera outbreak since 2007, and “some residents of the capital Conakry are clamoring to be vaccinated,” IRIN reports. “The cholera vaccine has shown promising results in the handful of communities where it has been used: none of those vaccinated have been infected,” the news service writes, noting, “For now cholera vaccination is not generally done on a large scale.” According to IRIN, “WHO and partner agencies are planning a cholera vaccine stockpile for epidemic control and looking at the possibility of introducing the two-dose oral vaccine into national immunization programs in endemic areas,” but the agency also “says such stockpiles should not detract from other prevention efforts: detection, diagnosis, and treatment of cases with oral rehydration and antibiotics; establishment of a safe water supply; implementation of adequate waste disposal, sanitation, and hygiene; and communication and social mobilization.”
The first-ever results from a dengue virus vaccine clinical trial aimed at showing effectiveness “provide signals rather than definitive answers, and a mixture of both promise and unresolved challenges,” Orin Levine, executive director of the International Vaccine Access Center, and Ciro de Quadros, executive vice president of the Sabin Vaccine Institute, write in the Huffington Post “Impact” blog. “To date, these represent the most promising indications that a safe, effective vaccine to prevent dengue is technically feasible,” they continue, adding, “At the same time, the results on protection were inconclusive, somewhat inconsistent with the measured immune responses and uneven across the four strains included in the vaccine.”
The annual number of child deaths worldwide has fallen more than 40 percent since 1990, “the result of myriad improvements in nutrition, access to vaccines and antibiotics, cleaner deliveries, better care of infants immediately after birth, and the use of insecticide-treated mosquito nets,” according to “the findings of a report released Wednesday by three United Nations agencies and the World Bank,” the Washington Post reports (Brown, 9/12). “In 1990, there were 12 million deaths of young children, but the latest figures … show that deaths had fallen by nearly half, to 6.9 million, by 2011,” the Guardian writes (Boseley, 9/12). “[T]he number of deaths is down by at least 50 percent in eastern, western and southeastern Asia, as well as in northern Africa, Latin America and the Caribbean,” the report says, VOA News notes (Schlein, 9/12). However, “[i]n some, mainly sub-Saharan countries, the total number of deaths of children younger than five increased,” BBC News writes, adding, “The Democratic Republic of Congo, Chad, Somalia, Mali, Cameroon, and Burkina Faso saw annual deaths of children under five rise by 10,000 or more in 2011 as compared with 1990” (Doyle, 9/13).
“The World Health Organization (WHO) on Tuesday said Nigeria was not on track in the effort to eradicate wild polio virus before the end of December this year,” Leadership/AllAfrica.com reports. Speaking at the 24th Expert Review Committee (ERC) Meeting on Polio Eradication in Abuja, Bruce Aylward, WHO assistant director-general for polio, emergencies and country collaboration, said Nigeria had the tools and capacity to turn back the increasing number of polio cases that pose a “real and growing danger to international public health,” the news service notes. Aylward “recommended eight major steps for polio eradication for the country, including the implementation of the new house-based micro planning and monitoring method,” refresher training for all personnel to emphasize the emergency status declared by the WHO, and the identification and immunization of missed children and those in insecure areas, among others, according to the news service. ERC Chair Tomori Oyewale “called on Nigerians to change their attitude to polio eradication to ensure the success of the fight against the virus,” the news service writes (9/11).
“A paper published in Nature [on Monday] sheds light on how a vaccine can turn the immune system against [HIV] and so offer protection from infection,” Nature News reports, noting “[t]he results are also being presented at the AIDS Vaccine 2012 conference in Boston, Massachusetts, this week” (Callaway, 9/10). Previous results from a trial called RV144 showed that two vaccines, Sanofi’s Alvac and VaxGen’s Aidsvax, reduced the risk of HIV infection by 31 percent over three years when used together, compared with people who received a placebo, according to Bloomberg (Bennett, 9/10). Last year, researchers showed “that those who responded to the vaccine and fended off HIV tended to produce antibodies against a specific part of the virus’s protein shell called the V1/V2 loop,” Nature News writes, adding, “The study published [Monday] goes a stage further, showing that the people who were vaccinated yet still contracted HIV had been infected by viruses that had mutations in the V2 portion.”
“The leading candidate to become the world’s first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world’s population,” the New York Times reports. “Still, the study marked a milestone in the 70-year quest to develop such a vaccine, demonstrating that a safe and effective inoculation against dengue is feasible, researchers reported in a paper published online Monday in the Lancet,” the newspaper adds (Pollack, 9/10). “Tested among just over 4,000 children in rural Thailand who were badly exposed to the mosquito-borne fever, the vaccine had no side effects but only worked against three out of the four dengue strains,” Agence France-Presse writes (9/10).
Most Asian Countries Fail To Include Rotavirus Vaccine In National Immunization Programs Citing Cost As Barrier
“Most countries in Asia have yet to make the rotavirus vaccine part of their national immunization program (NIP), despite a World Health Organization (WHO) recommendation to do so,” IRIN reports. “Worldwide, rotavirus accounts for 37 percent of all diarrhea deaths in children under five with 95 percent of those deaths occurring in developing countries,” the news service states, noting, “There are no antibiotics or any other drug to fight the infection and since 2009 WHO has recommended the global use of the rotavirus vaccine.” Forty-one countries worldwide include rotavirus vaccine in their NIPs, but “only two countries in Asia — Philippines and Thailand — are vaccinating (or are about to) children against rotavirus,” according to IRIN. An email to IRIN from WHO’s Manila office stated, “Price continues to be an important barrier to introducing rotavirus vaccine,” the news service notes (9/7).
“With a completed trial in Thailand that offered evidence a vaccine could be developed to protect people from HIV, emerging science identifying antibodies against HIV, and a current trial testing a novel vaccine combination against the virus potentially producing more information in the next year, this is an exciting time to hold a conference, organizers of AIDS Vaccine 2012 say,” the Center for Global Health Policy’s “Science Speaks” blog reports. “AIDS Vaccine 2012, which begins this Sunday and runs through Wednesday in Boston, will bring together about 1,000 participants, 120 scientists and scholars, discussion of 440 research studies, and speakers that, along with Massachusetts Governor Deval Patrick and National Institute of Allergy and Infectious Diseases Director Anthony Fauci, will include researchers known for work in HIV treatment as prevention of transmission, pre-exposure antiretroviral treatment as prevention (PrEP — or pre-exposure prophylaxis), and topical microbicides,” the blog notes (Barton, 9/6).